BIOMAT Database Logo BIOMAT Database Logo

Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation. 1996

S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Research Center, Department of Pathology, La Fe Universitary Hospital, Valencia, Spain.

An increase in plasma plasminogen activator inhibitors (PAIs), fundamentally PAI type 2 (PAI-2), has been described in normal pregnancy probably because the placenta is the main source of the high plasma levels of this protein. Although we have previously described plasmatic alterations of these inhibitors in pregnancies complicated with intrauterine fetal growth retardation (IUGR), no reports have been published about placental PAI-2 mRNA expression. In the present study, the placental PAI-2 expression determined in pregnancies complicated with IUGR and in severe preeclamptic patients was compared with that of normal pregnancies in order to identify the placental cell types expressing PAI-2 and to determine whether the production of PAI-2 is altered in placentas from IUGR. In situ hybridization analyses show that the syncytiotrophoblasts are the cells with the greatest PAI-2 expression in placenta. We report that the significant decrease in plasma and placental PAI-2 levels in IUGR groups is fundamentally due to a diminished expression of PAI-2 mRNA in placenta.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D011225 Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. Toxemias, Pregnancy,EPH Complex,EPH Gestosis,EPH Toxemias,Edema-Proteinuria-Hypertension Gestosis,Gestosis, EPH,Hypertension-Edema-Proteinuria Gestosis,Preeclampsia,Preeclampsia Eclampsia 1,Pregnancy Toxemias,Proteinuria-Edema-Hypertension Gestosis,Toxemia Of Pregnancy,1, Preeclampsia Eclampsia,1s, Preeclampsia Eclampsia,EPH Toxemia,Eclampsia 1, Preeclampsia,Eclampsia 1s, Preeclampsia,Edema Proteinuria Hypertension Gestosis,Gestosis, Edema-Proteinuria-Hypertension,Gestosis, Hypertension-Edema-Proteinuria,Gestosis, Proteinuria-Edema-Hypertension,Hypertension Edema Proteinuria Gestosis,Of Pregnancies, Toxemia,Of Pregnancy, Toxemia,Pre Eclampsia,Preeclampsia Eclampsia 1s,Pregnancies, Toxemia Of,Pregnancy Toxemia,Pregnancy, Toxemia Of,Proteinuria Edema Hypertension Gestosis,Toxemia Of Pregnancies,Toxemia, EPH,Toxemia, Pregnancy,Toxemias, EPH
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D005317 Fetal Growth Retardation Failure of a FETUS to attain expected GROWTH. Growth Retardation, Intrauterine,Intrauterine Growth Retardation,Fetal Growth Restriction,Intrauterine Growth Restriction
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated

Related Publications

S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Fetal blood flow in pregnancies complicated by intrauterine growth retardation.
June 1987, Obstetrics and gynecology,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Fetal amino acids in normal pregnancies and in pregnancies complicated by intrauterine growth retardation.
January 1992, Early human development,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Placental protein measurements in complicated pregnancies. I. Intrauterine growth retardation.
December 1984, British journal of obstetrics and gynaecology,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Decreased annexin A5 mRNA placental expression in pregnancies complicated by fetal growth restriction.
April 2010, Thrombosis research,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Fetal blood flow velocity waveforms in pregnancies complicated by intrauterine growth retardation.
May 1990, Israel journal of medical sciences,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Intrauterine growth in twin pregnancies: prediction of fetal growth retardation.
July 1985, Obstetrics and gynecology,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Altered mRNA expression pattern of placental epidermal growth factor receptor (EGFR) in pregnancies complicated by preeclampsia and/or intrauterine growth retardation.
January 1998, American journal of perinatology,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Essential fatty acids in pregnancies complicated by intrauterine growth retardation.
December 1991, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
[Doppler assessment of the fetal asphyxia in pregnancies complicated by gestational hypertension and intrauterine growth retardation].
March 2006, Ginekologia polska,
S Grancha, and A Estellés, and J Gilabert, and M Chirivella, and F España, and J Aznar
Coagulation and fibrinolysis in pregnancies complicated by fetal growth retardation.
May 1976, British journal of obstetrics and gynaecology,
Copied contents to your clipboard!